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In July 2016 the then Public Health Minister Jane Ellison announced that Human 
Papilloma Virus (HPV) primary screening would be implemented into the English 
cervical screening programme. HPV primary screening involves testing all cervical 
samples for HPV and undertaking cytology only on samples that are HPV positive. 
Nurses and Primary Care staff involved in cervical screening will therefore benefit 
from an understanding of the background to the introduction of HPV testing and the 
potential benefits of its introduction as a primary test in cervical screening.  
 
Women aged 25-49 (24 ½ in England) are invited for cervical screening (previously 
referred to as smear test) every three years and screening is undertaken every 5 years 
in women aged 50-64. Cervical screening can detect early changes in cervical cells, 
which if left undetected and untreated could lead to cancer of cervix. It is estimated 
that cervical screening saves 4500 lives annually (NHSCSP, 2016). Cancer of the 
cervix is the twelfth most common cancer in women in the UK. 
 
Background 
 
The decision to implement HPV primary screening in the cervical screening 
programme follows on from the report of the ARTISTIC Trial (A randomised trial of 
HPV testing in primary cervical screening) (Kitchener et al 2009). The ARTISTIC 
trial was conducted in six pilot sites throughout England and investigated HPV as a 
primary screening test. The trial results provided evidence for the use of HPV testing 
in the cervical screening programme either in addition to cervical cytology or as a 
stand-alone test. The UK National screening programme (UKNSC) advises ministers 
and the NHS in the 4 UK countries about population screening and in February 2016, 
the UKNSC recommended the cervical screening programme should adopt HPV as a 
primary screening tool and sought ministerial approval, which was granted in July 
2016.  
 
Cervical screening identifies apparently healthy women who may be at increased risk 
of developing cervical cancer, early detection of cell changes enables better treatment 
and prognosis. A cervical screening test involves the visualisation of the cervix using 
a speculum and obtaining a sample of the cervical squamo-columnar junction. A 
trained and competent registered professional can provide the appropriate 
communication, empathy, skill and assurance required for the individual woman to 
have confidence in the test (Public Health England, 2016). 
Nurses and Primary Care staff involved in cervical screening will therefore benefit 
from an understanding of the background to the introduction of HPV testing and the 
potential benefits of its introduction as a primary test in cervical screening.  
 
Currently, cervical screening involves the detection of abnormal epithelial cells from 
a sample of exfoliative cervical cells obtained using a cervexbrush and liquid based 
cytology (LBC) for sample saving. The  discovery of the role of HPV in the 
development of cervical cancer in the early 1990’s (Walboomers et al 1999)  led to 
the inclusion of HPV testing in routine cervical screening in 2015 with HPV testing of 
samples in women with borderline or mild dyskaryosis (this is referred to a HPV 
triage). Women who test positive for HPV are referred to colposcopy. 
 
 
HPV Primary Screening 
 
Liquid-based cytology (LBC) was implemented in the UK in 2008 as a means for 
cervical sample saving, for transfer to a laboratory for testing; HPV primary screening 
can be conducted on an LBC cervical sample and a variety of tests are available for 
this purpose. Most of the tests are based on the detection of viral DNA.  HPV DNA 
testing has been developed because a high-risk HPV positive test provides the basis 
for further investigation (Colposcopy) and possible treatment.  
 
HPV is the term used to describe a collection of viruses that affect the skin and moist 
membrane that line the body’s orifices such as the cervix, anus, mouth and throat. 
99.9% of cervical cancers are caused by HPV (Wallboomers et al,1999). Anyone who 
is sexually active can contract HPV through contact with someone who already has 
the virus. Most people are infected with HPV at some point in their lives and HPV 
infection is so common that it can be considered a normal consequence of having sex.  
Most people are infected with HPV at some point in their lives. However, there are 
around eight high-risk types of HPV that are responsible for 90% of all cervical 
cancers. These are referred to High-Risk HPV types. Within the high-risk group, 
types 16 & 18 are  responsible for about 70% of cervical cancers. The remaining 20% 
of leisons are associated with HPV types 31,33,34,45,52 & 58 (DeSanjose 2010).  If 
undetected and left untreated these changes can lead to cervical intraepithelial 
neoplasia (CIN) and cancer of cervix. (see diagram 1).  
 
 
 
 
  
With the introduction of HPV primary testing women who are HPV negative will be 
returned to routine recall (3 or 5 yearly depending on age). A result which is HPV 
negative places a woman at very low risk of developing cervical cancer (Walboomers 
et al, 1999). Diagram 1 illustrates the process from initial test to outcome. 
 
 
Diagram 1 Reproduced with permission from Jo’s cervical cancer trust. 
 
The rationale for the introduction of HPV Primary screening as opposed to cytology is 
based on the greater sensitivity of the HPV to detect CIN and to address the inclusion 
of women who have received HPV vaccination (Kitchener, 2105). In the UK, HPV 
primary prevention through vaccination of girls aged 12-13 commenced in September 
2008 alongside a 3 year catch –up programme to target girls up to 18 years. The 
uptake rates for HPV vaccination in the UK has been high with 90% of girls aged 12-
13 completing the course (Public Health England, 2013). 
 
 
 
Results from the ARTISTIC trial  
 
The ARTISTIC trial commenced in 2001 and involved six pilot sites in Manchester, 
Stockport, Wigan, Leith, Salford and Trafford and investigated the role of HPV 
testing within the national screening programme. The study population comprised of 
25,000 women aged 20-64 who were attending general practices for routine cervical 
screening and who consented to having the HPV test (Kitchener & Almonte, 2006).  
Moss & Gibney (2015) in their evaluation report of the ARTISTIC trial to the national 
screening committee collated the data received from all sites on HPV primary 
screening for samples received up to 31.10.2014. The data include a total of 167,919 
primary HPV tests and 331,995 primary cytology samples. The pilot sites were 
partially converted to primary HPV screening and results for primary HPV testing are 
compared to those for primary cytology screening in the same sites.  
 
Of the study population, 12.9% (21682) tested positive for HPV and subsequent 
colposcopy indicated that 2.9% (4841) had borderline dyskaryotic changes and a 
further 2.3% (2232) had dyskaryosis which was moderate or worse.  They concluded 
that baseline screening by HPV primary testing achieves a higher detection rate for 
CIN 2 or worse.  
 
Higher HPV positive rates were detected in women in the 25-29 age group. However 
HPV positivity will decline once the HPV vaccinated cohort reaches screening age 
from 2016 onwards (Moss & Gibney,2015). HPV vaccination was introduced in 2008 
and is offered to girls aged 12-13 years, and included a catch-up programme for girls 
up to age 18 at the time of its introduction.  
Kitchener (2015) reported that high-risk HPV testing is superior to cytology in terms 
of sensitivity for high grade cervical intraepithelial neoplasia (CIN).   The risk of CIN 
3+ developing in women found to have HR-HPV infection could be determined from 
the ARTISTIC trial data. HPV negative women had a 0.28% risk of CIN3+ over a 6 
year period compared with women with High-risk HPV 16 which was associated with 
a 100 fold increase in the development of CIN3+.  
Increase in screening intervals 
 
Ronco et al (2014) in a follow-up study of the analysis of four European randomised 
controlled trials which compared HPV based screening for cervical cancer with 
cytology-based screening recorded that the incidence of cervical cancer was lower 5.5 
years after a negative HPV test than 3.5 years after a negative cytology result, 
indicating that 5 year intervals for HPV screening are safer than 3-year intervals for 
cytology. 
 
Likewise data from the ARTISTIC trial specifically, indicated that 6 yearly screening 
until age 50 and 10 yearly screening over 50 would be as effective as the current three 
yearly (women aged 25-49)and five  (women age 50-64) yearly screening intervals, 
thus potentially allowing women to be screened less frequently in the future. 
 
 
 
 
 
Other potential benefits of HPV testing  
 
Uptake of cervical screening continues to decline throughout the UK. In March 2016 
the uptake of cervical screening in women aged 25-64 was 72.7%. This compares 
with 73.5% in 2015.  Women in the 25-49 age group have the lowest attendance at 
70.2% compared with 71.5% in 2015. Several reasons are quoted for non-
participation including fear of the procedure, embarrassment, lack of clinic provision,   
lack of understanding of the risks of cervical cancer and the purpose of cervical 
screening (Kothari, 2016).  
 
HPV testing can be carried out on a self-taken sample and HPV primary testing using 
self-sampling kits is a strategy that might encourage a number of women who have 
not attended for screening to gain information about their potential risk. Self-collected 
samples are already in use in the bowel screening and chlamydia screening 
programme. Racey et al (2013) in their systematic review of eight European studies of 
under-screened women found that compliance with HPV self-testing was significantly 
higher that with cervical cytology. However, with regards to HPV self-sampling 
Cadman et al (2015) in a study of Hindu women reluctant to attend for screening 
noted that efforts would need to be made to build the confidence of women regarding 
the quality of the sample they could collect.   
 
 
 
Changes to Practice  
 
Cervical screening is a well-established programme and new developments have been 
incorporated successfully into the programme since its inception in 1988. The 
introduction of HPV primary screening will require practitioners involved to be 
knowledgeable regarding the background and rationale for the planned changes in 
cervical screening provision and to be able to advise women about the changes to the 
programme and how this will impact on individual screening experiences.  
 
 
The introduction of primary HPV screening will require significant changes to the 
existing screening programme. Public Health England (2016) have acknowledged that 
many aspects remain to be discussed including the introduction of a  new cervical 
screening pathway taking into account the individual woman’s screening result. New 
IT systems will be required and Laboratory staff training and future laboratory 
workforce requirements will need to be considered. 
 
As practitioners we should endeavour to remain informed about the proposed 
changes.  
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